Om

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy and other serious cardiovascular diseases. Its lead program centers on BHB-1893, an oral small-molecule cardiac myosin inhibitor designed for both obstructive and non-obstructive forms of the disease. The company’s work is aimed at advancing treatment options for patients with limited therapeutic choices, with a focus on cardiovascular medicine and heart muscle disorders. Braveheart Bio operates as a drug-development company, supporting research and clinical development across its current pipeline rather than commercial product sales. Headquartered in San Francisco, California, Braveheart Bio was incorporated in 2024 and is positioned within the biotechnology sector as a developer of specialized cardiovascular therapies.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BRAVEHEART BIO MED ENDAVU: Køb Braveheart Bio ($BRVE) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Braveheart Bio, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.